IM-12 | CAS#1129669-05-1 | GSK-3β inhibitor

IM-12
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522433

CAS#: 1129669-05-1

Description: IM-12 is a cell-permeable indolylmaleimide that acts as a GSK-3β inhibitor. IM-12 is potent and selective enhances canonical Wnt signalling. IM-12 inhibits GSK-3β activity and subsequently increases β-catenin concentration significantly in hNPCs. When used to treat human neural progenitor cells, IM-12 promoted neuronal differentiation resulting in an increase of neuronal cells.

Chemical Structure

IM-12

CAS# 1129669-05-1

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 522433
Name: IM-12
CAS#: 1129669-05-1
Chemical Formula: C22H20FN3O2
Exact Mass: 377.15
Molecular Weight: 377.419
Elemental Analysis: C, 70.01; H, 5.34; F, 5.03; N, 11.13; O, 8.48

Price and Availability

Size	Price	Availability
50mg	USD 450
100mg	USD 750
200mg	USD 1250
500mg	USD 2650	2 Weeks
1g	USD 3650	2 Weeks
2g	USD 5950	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: IM-12; IM12; IM 12

IUPAC/Chemical Name: 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione

InChi Key: ZKJAZFUFPPSFCO-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H20FN3O2/c1-13-18(16-5-3-4-6-17(16)25-13)19-20(22(28)26(2)21(19)27)24-12-11-14-7-9-15(23)10-8-14/h3-10,24-25H,11-12H2,1-2H3

SMILES Code: FC(C=C1)=CC=C1CCNC(C2=O)=C(C(N2C)=O)C(C3=C(C=CC=C3)N4)=C4C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	IM-12 is an inhibitor of GSK-3β, with an IC50 of 53 nM, and also enhances Wnt signalling.
In vitro activity:	This study then determined whether GSK-3β was required for the TP53INP2 knockdown-mediated inhibition of EMT. As shown in Figure 4A–C, the administration of IM-12, an inhibitor of GSK-3β, abrogated the reduction of migration and invasion caused by TP53INP2 knockdown in the BIU87 and EJ cells. In addition, the TP53INP2 knockdown-induced decrease in non-phospho (active) β-catenin and Snail1 were blocked by IM-12 (Figure 4D). The TP53INP2 knockdown-induced EMT suppression was also abrogated by the administration of IM-12, indicating that the effect on EMT mediated by TP53INP2 knockdown was dependent on GSK-3β (Figure 4D). Reference: Onco Targets Ther. 2020 Sep 28;13:9587-9597. https://pubmed.ncbi.nlm.nih.gov/33061441/
In vivo activity:	TBD

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMF	50.0	132.48
	DMF:PBS (pH 7.2) (1:4)	0.2	0.53
	DMSO	53.3	141.22
	Ethanol	5.5	14.57

Preparing Stock Solutions

The following data is based on the product molecular weight 377.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Zhou Z, Liu X, Li Y, Li J, Deng W, Zhong J, Chen L, Li Y, Zeng X, Wang G, Zhu J, Fu B. TP53INP2 Modulates Epithelial-to-Mesenchymal Transition via the GSK-3β/β-Catenin/Snail1 Pathway in Bladder Cancer Cells. Onco Targets Ther. 2020 Sep 28;13:9587-9597. doi: 10.2147/OTT.S251830. PMID: 33061441; PMCID: PMC7532081.
In vitro protocol:	1. Zhou Z, Liu X, Li Y, Li J, Deng W, Zhong J, Chen L, Li Y, Zeng X, Wang G, Zhu J, Fu B. TP53INP2 Modulates Epithelial-to-Mesenchymal Transition via the GSK-3β/β-Catenin/Snail1 Pathway in Bladder Cancer Cells. Onco Targets Ther. 2020 Sep 28;13:9587-9597. doi: 10.2147/OTT.S251830. PMID: 33061441; PMCID: PMC7532081.
In vivo protocol:	TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Dadarwal D, Mapletoft RJ, Adams GP, Pfeifer LF, Creelman C, Singh J. Effect of progesterone concentration and duration of proestrus on fertility in beef cattle after fixed-time artificial insemination. Theriogenology. 2013 Mar 15;79(5):859-66. doi: 10.1016/j.theriogenology.2013.01.003. PubMed PMID: 23394971.

2: Heikal NM, Bader FM, Martins TB, Pavlov IY, Wilson AR, Barakat M, Stehlik J, Kfoury AG, Gilbert EM, Delgado JC, Hill HR. Immune function surveillance: association with rejection, infection and cardiac allograft vasculopathy. Transplant Proc. 2013 Jan-Feb;45(1):376-82. doi: 10.1016/j.transproceed.2012.04.034. Epub 2012 Sep 18. PubMed PMID: 23267802.

3: Man WL, Chen G, Yiu SM, Shek L, Wong WY, Wong WT, Lau TC. Formation of μ-dinitrogen (salen)osmium complexes via ligand-induced N···N coupling of (salen)osmium(VI) nitrides. Dalton Trans. 2010 Dec 14;39(46):11163-70. doi: 10.1039/c0dt00481b. Epub 2010 Oct 21. PubMed PMID: 20963250.

4: Schmöle AC, Brennführer A, Karapetyan G, Jaster R, Pews-Davtyan A, Hübner R, Ortinau S, Beller M, Rolfs A, Frech MJ. Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells. Bioorg Med Chem. 2010 Sep 15;18(18):6785-95. doi: 10.1016/j.bmc.2010.07.045. Epub 2010 Jul 25. PubMed PMID: 20708937.

5: Nørregaard R, Jensen BL, Topcu SO, Wang G, Schweer H, Nielsen S, Frøkiaer J. Urinary tract obstruction induces transient accumulation of COX-2-derived prostanoids in kidney tissue. Am J Physiol Regul Integr Comp Physiol. 2010 Apr;298(4):R1017-25. doi: 10.1152/ajpregu.00336.2009. Epub 2010 Feb 10. PubMed PMID: 20147610; PubMed Central PMCID: PMC2853392.

6: GREINER RA, Braathen LR. Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system. Eur J Dermatol. 2009 Sep-Oct;19(5):494-9. doi: 10.1684/ejd.2009.0725. Epub 2009 Jun 5. PubMed PMID: 19502153.

7: Gdynia HJ, Müller HP, Ludolph AC, Köninger H, Huber R. Quantitative muscle ultrasound in neuromuscular disorders using the parameters 'intensity', 'entropy', and 'fractal dimension'. Eur J Neurol. 2009 Oct;16(10):1151-8. doi: 10.1111/j.1468-1331.2009.02663.x. Epub 2009 May 22. PubMed PMID: 19486136.

8: Elliot TA, Cree MG, Sanford AP, Wolfe RR, Tipton KD. Milk ingestion stimulates net muscle protein synthesis following resistance exercise. Med Sci Sports Exerc. 2006 Apr;38(4):667-74. PubMed PMID: 16679981.

9: Cavalieri J, Hepworth G, Fitzpatrick LA. Synchronising oestrus with oestradiol benzoate after using a two-dose prostaglandin treatment to synchronise luteolysis in dairy heifers. Aust Vet J. 2005 Jan-Feb;83(1-2):91-6. PubMed PMID: 15971828.

10: Sun WH, Yu Q, Shen H, Ou XL, Cao DZ, Yu T, Qian C, Zhu F, Sun YL, Fu XL, Su H. Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis. World J Gastroenterol. 2004 Oct 1;10(19):2809-13. PubMed PMID: 15334675; PubMed Central PMCID: PMC4572107.

11: Paillaud JL, Harbuzaru B, Patarin J, Bats N. Extra-large-pore zeolites with two-dimensional channels formed by 14 and 12 rings. Science. 2004 May 14;304(5673):990-2. PubMed PMID: 15143276.

12: Leverge R, Bergmann JF, Simoneau G, Tillet Y, Bonnemain B. Bioavailability of oral vs intramuscular iodinated oil (Lipiodol UF) in healthy subjects. J Endocrinol Invest. 2003;26(2 Suppl):20-6. PubMed PMID: 12762636.

13: Lukac J, Mravak-Stipetić M, Knezević M, Vrcek J, Sistig S, Ledinsky M, Kusić Z. Phagocytic functions of salivary neutrophils in oral mucous membrane diseases. J Oral Pathol Med. 2003 May;32(5):271-4. PubMed PMID: 12694350.

14: Crane J, Armson A, Brunner M, De La Ronde S, Farine D, Keenan-Lindsay L, Leduc L, Schneider C, Van Aerde J; Executive Committee of the Society of Obstetricians and Gynaecologists of Canada. Antenatal corticosteroid therapy for fetal maturation. J Obstet Gynaecol Can. 2003 Jan;25(1):45-52. English, French. PubMed PMID: 12548324.

15: Rittichier KK, Ledwith CA. Outpatient treatment of moderate croup with dexamethasone: intramuscular versus oral dosing. Pediatrics. 2000 Dec;106(6):1344-8. PubMed PMID: 11099587.

16: Palta P, Kumar M, Jailkhani S, Manik RS, Madan ML. Changes in peripheral inhibin levels and follicular development following treatment of buffalo with PMSG and Neutra-PMSG for superovulation. Theriogenology. 1997 Jul 15;48(2):233-40. PubMed PMID: 16728122.

17: Hemsén A, Modin A, Weitzberg E. Increased concentrations of endothelin-1 messenger RNA in tissues and endothelin-1 peptide in plasma in septic pigs: modulation by betamethasone. Crit Care Med. 1996 Sep;24(9):1530-6. PubMed PMID: 8797627.

18: Thomas H Jr, Schwartz E, Petrilli R. Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Ann Emerg Med. 1992 Apr;21(4):407-13. PubMed PMID: 1554179.

19: Vige PM, Henrion RM. Thiamphenicol for treatment of salpingitis. Sex Transm Dis. 1984 Oct-Dec;11(4 Suppl):441-3. PubMed PMID: 6523325.

20: Braga PC, Marchi E, Scaglione F, Scarpazza G, Faravelli M, Fraschini F. Kinetics of penetration and clearance of mezlocillin in the bronchopulmonary tract. Int J Clin Pharmacol Res. 1984;4(5):361-5. PubMed PMID: 6519850.

Your view history

IM-12 featured